Zantac

On September 13, 2019, the U.S. Food and Drug Administration (FDA) reported the discovery of the carcinogenic contaminant N-nitrosodimethylamine (NDMA) in Zantac (ranitidine), a common heartburn medication available in both prescription and over-the-counter versions.

In April of 2020, the FDA announced that all Zantac brand heartburn drugs, prescription and over-the-counter, should be immediately pulled from the market because of potential NDMA contamination, a chemical linked to cancer.

In February 2020, an MDL was established for Zantac in federal court in Florida. Our law firm is serving on the Plaintiffs' Steering Committee and as head of the Science Committee in the MDL. As of October 2021, more than 1,500 lawsuits were pending in the MDL.

Criteria

- Minimum 1 year usage
- Cancer diagnosis before age 89
- Post 1/2000 diagnosis of one of the following cancers: Pancreatic, Esophageal, Stomach/gastric, Breast, Liver, Bladder, Colorectal/intestine, Kidney, Prostate (dx before age 70) or Lung (must be non-smoker for 20+ years)

https://www.levinlaw.com/zantac-lawsuits-bladder-stomach-cancer